Top

Published in:

01-08-2007 | Original Article

A Synergistic Antitumor Effect of Interleukin-2 Addition with CD80 Immunogene Therapy for Peritoneal Metastasis of Gastric Carcinoma

Authors: Kinshi Kosaka, Masakazu Yashiro, Yoji Sakate, Kosei Hirakawa

Published in: Digestive Diseases and Sciences | Issue 8/2007

Abstract

The co-stimulatory molecule CD80 is a ligand of CD28, which plays a key role in the induction of cell-mediated immune responses. Many tumors, including gastric cancer, decrease the expression of CD80, which results in the failure of immune recognition. We evaluated the effect of interleukin-2 addition combined with CD80 infection on the peritoneal metastasis in gastric cancer. CD80 infection combined with interleukin-2 addition significantly increased the activated cytotoxicity of mononuclear cells compared to CD80 gene infection and compared to the lacZ control group. In vivo, the survival of animals with intraperitoneal tumor was longest in those given CD80 infection with interleukin-2 addition (median survival, 46 days), followed by those given interleukin-2 (39 days), those given CD80 infection (37 days), and those given lacZ (29 days). These results suggest that interleukin-2 addition might contribute to improving the observed outcome of CD80 immunogene therapy in peritoneal metastasis of gastric carcinoma.

Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M (1996) Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as “soil” for peritoneal dissemination. Cancer 77:1668–1675PubMed

Matsuoka T, Hirakawa K, Chung YS, Yashiro M, Nishimura S, Sawada T, Saiki I, Sowa M (1998) Adhesion polypeptides are useful for the prevention of peritoneal dissemination of gastric cancer. Clin Exp Metastasis 16:381–388PubMedCrossRef

Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M (1995) Establishment of two new scirrhous gastric cancer cell lines:analysis of factors associated with disseminated metastasis. Br J Cancer 72:1200–1210PubMed

Putzer BM, Hitt M, Muller WJ, Emtage P, Gauldie J, Graham FL (1997) Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci USA 94:10889–10894PubMedCrossRef

Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C (1993) B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76–79PubMedCrossRef

Linsley PS, Ledbetter JA (1993) The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11:191–212PubMed

Chen L, Linsley PS, Hellstrom KE (1993) Costimulation of T cells for tumor immunity. Immunol Today 14:483–486PubMedCrossRef

Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM (1989) B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 143:2714–2722PubMed

Emtage PC, Wan Y, Bramson JL, Graham FL, Gauldie J (1998) A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model. J Immunol 160:2531–2538PubMed

10.

Si L, Si H, Chen Y, Sun Y, Wing Y (1999) B7-1 antigen expression in tumor cells from cancerous human tissues. Anal Quant Cytol Histol 21:521–526PubMed

11.

Koyama S, Maruyama T, Adachi S, Nozue M (1998) Expression of costimulatory molecules, B7-1 and B7-2 on human gastric carcinoma. J Cancer Res Clin Oncol 124:383–388PubMedCrossRef

12.

Robb RJ, Munck A, Smith KA (1981) T cell growth factor receptors. Quantitation, specificity, biological relevance. J Exp Med 154:1455–1474PubMedCrossRef

13.

Taniguchi T, Minami Y (1993) The IL-2/IL-2 receptor system: a current overview. Cell 73:5–8PubMedCrossRef

14.

Cayeux S, Richter G, Becker C, Beck C, Aicher A, Pezzutto A, Dorken B, Blankenstein T (1997) Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency. Eur J Immunol 27:1657–1662PubMedCrossRef

15.

Antonia SJ, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo MJ, Friberg M, Alsarraj M, Mahany JJ, Pow-Sang J, Cantor A, Janssen W (2002) Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 167:1995–2000PubMedCrossRef

16.

Dabrosin C, Palmer K, Gauldie J (2003) Oestradiol enhances tumour regression induced by B7-1/IL-2 adenoviral gene transfer in a murine model of breast cancer. Br J Cancer 89:385–390PubMedCrossRef

17.

Larchian WA, Horiguchi Y, Nair SK, Fair WR, Heston WD, Gilboa E (2000) Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. Clin Cancer Res 6:2913–2920PubMed

18.

Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M (1996) Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Clin Exp Metastasis 14:43–54PubMedCrossRef

19.

Kanegae Y, Makimura M, Saito I (1994) A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol 47:157–166,PubMed

20.

Mizuguchi H, Kay MA (1999) A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 10:2013–2017PubMedCrossRef

21.

Mizuguchi H, Kay MA (1998) Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 9:2577–2583PubMedCrossRef

22.

Sunami T, Yashiro M, Chung KH (2000) ICAM-1 (intercellular adhesion molecule-1) gene transfection inhibits lymph node metastasis by human gastric cancer cells. Jpn J Cancer Res 91:925–933PubMed

23.

Yoshimura A, Shiku H, Nakayama E (1993) Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4–CD8– T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice. J Immunol 150:4900–4910PubMed

24.

Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589–601PubMed

25.

Tanaka Y, Albelda SM, Horgan KJ, van Seventer GA, Shimizu Y, Newman W, Hallam J, Newman PJ, Buck CA, Shaw S (1992) CD31 expressed on distinctive T cell subsets is a preferential amplifier of beta 1 integrin-mediated adhesion. J Exp Med 176:245–253PubMedCrossRef

26.

Shimizu Y, Newman W, Gopal TV, Horgan KJ, Graber N, Beall LD, van Seventer GA, Shaw S (1991) Four molecular pathways of T cell adhesion to endothelial cells: roles of LFA-1, VCAM-1, ELAM-1 and changes in pathway hierarchy under different activation conditions. J Cell Biol 113:1203–1212PubMedCrossRef

27.

Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS (1981) Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1:51–63PubMedCrossRef

28.

Henke PK, DeBrunye LA, Strieter RM, Bromberg JS, Prince M, Kadell AM, Sarkar M, Londy F, Wakefield TW (2000) Viral IL-10 gene transfer decreases inflammation and cell adhesion molecule expression in a rat model of venous thrombosis. J Immunol 164:2131–2141PubMed

29.

Sakate Y, Yashiro M, Tanaka H, Kosaka K, Ohira M, Hirakawa K (2004) Suppression of peritoneal metastasis in human gastric carcinoma by enhanced immunogenicity of B7-1 transfection. Oncol Rep 12:53–57PubMed

30.

Townsend SE, Su FW, Atherton JM, Allison JP (1994) Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 54:6477–6483PubMed

31.

Mulcahy KA, Alexander S, Platts KE, Wardle C, Sisley K, Rennie IG, Murray AK (2002) CD80-mediated induction of immunostimulation in two ocular melanoma cell lines is augmented by interferon-gamma. Melanoma Res 12:129–138PubMedCrossRef

32.

Miyazono Y, Kamogawa Y, Ryo K, Furukawa T, Mitsuhashi M, Yamauchi K, Kameoka T, Hayashi N (1999) Effect of B7. 1-transfected human colon cancer cells on the induction of autologous tumour-specific cytotoxic T cells. J Gastroenterol Hepatol 14:997–1003PubMedCrossRef

33.

Lundqvist A, Choudhury A, Nagata T, Andersson T, Quinn G, Fong T, Maitland N, Pettersson S, Paulie S, Pisa P (2002) Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis. Hum Gene Ther 13:1541–1549PubMedCrossRef

34.

Liu B, Podack ER, Allison JP, Malek TR (1996) Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J Immunol 156:1117–1125PubMed

35.

Von Gruenigen VE, O’Boyle JD, Coleman RL, Wilson D, Miller DS, Mathis JM (1999) Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer. Int J Gynecol Cancer 9:365–372PubMedCrossRef

36.

Tsunemitsu Y, Kagawa S, Tokunaga N, Otani S, Umeoka T, Roth JA, Fang B, Tanaka N, Fujiwara T (2004) Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer. Gut 53:554–560PubMedCrossRef

37.

Shiratori Y, Kanai F, Hikiba Y, Moriyama H, Hamada H, Matsumura M, Tanaka T, Lan KH, Ohashi M, Okano K, Naito M, Omata M (1998) Gene therapy for hepatic micrometastasis of murine colon carcinoma. J Hepatol 28:886–895PubMedCrossRef

38.

Yasumura S, Lin WC, Weidmann E, Hebda P, Whiteside TL (1994) Expression of interleukin 2 receptors on human carcinoma cell lines and tumor growth inhibition by interleukin 2. Int J Cancer 59:225–234PubMedCrossRef

39.

Tanaka H, Yashiro M, Sunami T, Sakate Y, Kosaka K, Hirakawa K (2004) ICAM-2 gene therapy for peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res 10:4885–4892PubMedCrossRef

Title: A Synergistic Antitumor Effect of Interleukin-2 Addition with CD80 Immunogene Therapy for Peritoneal Metastasis of Gastric Carcinoma
Authors: Kinshi Kosaka
Masakazu Yashiro
Yoji Sakate
Kosei Hirakawa
Publication date: 01-08-2007
Publisher: Kluwer Academic Publishers-Plenum Publishers
Published in: Digestive Diseases and Sciences / Issue 8/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-006-9637-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2007

Alterations in Epithelial and Mesenchymal Intestinal Gene Expression During Doxorubicin-Induced Mucositis in Mice

Significance of Enhanced Expression of Nitric Oxide Syntheses in Splenic Sinus Lining Cells in Altered Portal Hemodynamics of Idiopathic Portal Hypertension

Achalasia in Iceland, 1952–2002: An Epidemiologic Study

Prescribing Patterns and Awareness of Adverse Effects of Infliximab: A Health Survey of Gastroenterologists

Applying Data Mining Techniques in the Development of a Diagnostics Questionnaire for GERD

Bowel Habit Reference Values and Abnormalities in Young Iranian Healthy Adults

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials